Delivery Order SPE2DB20D1109-SPE2DB23FP18U
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,178.96 delivery order contract is for the supply of XCOPRI 200 MG TABLET 30S, a pharmaceutical product. The contract has a period of performance ending on June 12, 2025 and is a firm fixed-price delivery order with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a larger...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,639.77 firm fixed-price delivery order is for the supply of XCOPRI 50 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of April 3, 2025 and is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,011.66 firm fixed-price delivery order is for the supply of XCOPRI 50 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of February 26, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,158.27 firm fixed-price delivery order is for the supply of XCOPRI 100 MG TABLET 30S, a prescription medication. The contract has an ultimate completion date of May 20, 2025 and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant $999,999,999.00...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,476.24 firm fixed-price delivery order is for the supply of XCOPRI 150 MG tablets to support military healthcare programs. The contract has an ultimate completion date of January 17, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,372.96 firm fixed-price delivery order is for the supply of XCOPRI 100 MG TABLET 30S, a pharmaceutical product, with a completion date of March 21, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,224.37 firm-fixed-price delivery order is for the supply of XCOPRI 200 MG TABLET 30S, a pharmaceutical product. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,082.68 firm-fixed-price delivery order is for the supply of XCOPRI 100 MG TABLET 30S, a medical product. The contract has a completion date of July 29, 2024 and was awarded on July 26, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,433.68 firm fixed-price delivery order contract is for the supply of XCOPRI 100 MG TABLET 30S, a type of pharmaceutical product. The contract has an ultimate completion date of January 9, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award is a delivery order from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,709.34 firm fixed-price contract is for the delivery of XCOPRI 100 MG TABLET 30S, a pharmaceutical product, through November 2024. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB23FP18UDelivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,918.68 firm fixed-price delivery order is for the supply of XCOPRI 200 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of May 23, 2023 and was awarded on May 22, 2023. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen Drug Corp holds with the DLA Troop Support Medical. The IDC, which runs through November 2026, serves as a primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which also holds a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 5/22/23 |